Supersaturating Drug Delivery Systems (SDDS) could enhance oral bioavailability of poorly water soluble drugs (PWSD). Precipitation inhibitors (PIs) in SDDS could maintain supersaturation by inhibiting nucleation, crystal growth, or both. The mechanisms by which these effects are realized are generally unknown. The goal of this dissertation was to explore the mechanisms underpinning the effects of model PIs including hydroxypropyl β-cyclodextrins (HP-β-CD), hydroxypropyl methylcellulose (HPMC), and polyvinylpyrrolidone (PVP) on the crystal growth of indomethacin, a model PWSD. At high degrees of supersaturation (S), the crystal growth kinetics of indomethacin was bulk diffusion-controlled, which was attributed to a high energy form deposited on the seed crystals. At lower S, indomethacin growth kinetics was surface integration-controlled. The effect of HP-β-CD at high S was successfully modeled using the reactive diffusion layer theory. The superior effects of PVP and HPMC as compared to HP-β-CD at high S were attributed to a change in the rate limiting step from bulk diffusion to surface integration largely due to prevention of the high energy form formation. The effects of PIs at low S were attributed to significant retardation of the surface integration rate, a phenomenon that may reflect the adsorption of PIs onto the growing surface. PVP was selected to further understand the relationship between adsorption and crystal growth inhibition. The Langmuir adsorption isotherm model fit the adsorption isotherms of PVP and N-vinylpyrrolidone well. The affinity and extent of adsorption of PVP were significantly higher than those of N-vinylpyrrolidone, which was attributed to cooperative interactions between PVP and indomethacin. The extent of PVP adsorption on a weight-basis was greater for higher molecular weight PVP but less on a molar-basis indicating an increased percentage of loops and tails for higher molecular weight PVPs. PVP significantly inhibited indomethacin crystal growth at high S as compared to N-vinylpyrrolidone, which was attributed to a change in the growth mechanism resulting in a change in the rate limiting step from bulk diffusion to surface integration. Higher molecular weight PVPs were better inhibitors than lower molecular weight PVPs, which was attributed to a greater crystal growth barrier provided by a thicker adsorption layer.

siRNA therapy is an emerging technique that reduces protein expression in cells by degrading their mRNAs via the RNA interference pathway (RNAi). Diseases such as cancer often proliferate due to increased protein expression and siRNA therapy offers a new method of treatment for those diseases. Although siRNA therapy has shown success in vitro, it often fails in vivo due to instability in the blood stream. To overcome this limitation, delivery vehicles are necessary for successful transfection of siRNA into target cells and cationic polymers have been widely studied for this purpose. However, complexes between siRNA and delivery vehicles made from cationic polymers exhibit stability issues in the blood stream which results in toxicity and low transfection. This work hypothesizes that improvement of vehicle/siRNA complex stability will improve siRNA transfection efficiency. To test this, the contributions and outcomes of poly(ethylene glycol) [PEG] shell and hydrophobic core modification to a polyethylenimine (PEI) based tethered nanoassemblies (TNAs) were examined. Initially, hydrophobic modification of palmitate (PAL) to the core of the TNA yielded improved transfection efficiency due to an enhanced endosomal escape capability. However, this modification also reduced the TNA/siRNA complex stability. This indicated that the core hydrophobicity must be balanced in order increase stability while increasing transfection efficiency. Additionally, TNAs made from PEG and PEI did not cause transfection in our initial study. The PEG shell density was found to be too great and thereby reduced transfection efficiency. Reducing the PEG density by lowering PEG molecular weight, reducing attachment percentage, and removing small PEI impurities from the synthesis stock increased overall transfection efficiency and unimolecularity of the TNA complexes. This indicated that the shell composition of the TNA must be tuned in order to improve particle design. Further study of the hydrophobically modification to TNAs yielded unintended effects on the transfection efficiency evaluation assay. These particles exhibited an siRNA independent reduction in the reporter protein used to observe transfection, or a false positive effect, that was not previously observed. It was found that this false positive was influence mainly by the hydrophobic group rather than the cationic polymer backbone. Cellular stress was observed in cells dosed with the hydrophobically modified TNAs which lead to over ubiquitination and rapid degradation of the luciferase protein. This demonstrated that core components of TNAs could cause cellular stress and influence interaction outside of the TNA. Overall, this work demonstrates that hydrophobic core and PEG shell modification require balancing and consideration to improve properties of future cationic polymer based siRNA delivery vehicle design.

“Bath salts” and “plant food”, which were legally marketed synthetic cathinones, have a high potential for abuse. Several recent studies indicate that 3,4-methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxymethcathinone (methylone), two common drugs of this type, have similar pharmacology to controlled psychostimulants such as cocaine, methamphetamine, and methylphenidate. MDPV acts as a norepinephrine (NE) and dopamine (DA) reuptake inhibitor via blockade of their transporters (DAT and NET), whereas methylone is a substrate for the NE, DA, and serotonin (5-HT) transporters, increasing the non-vesicular release of these monoamines. Both drugs cause significant increases in the levels of these neurotransmitters in the cleft. Increases in DA are associated with euphoric effects and thus promote drug abuse and addiction, hence the high addiction potential of MDPV and methylone. Indeed, MDPV is 50 times more potent at the DAT and 10 times more potent at the NET than cocaine. Here, we examined the pharmacokinetics of MDPV and methylone in the brain and plasma, following intraperitoneal injection in mice. These types of injections have similar pharmacokinetics to insufflation (snorting), which is the manner in which MDPV and methylone are commonly abused. Briefly, adolescent male Swiss-Webster mice were injected intraperitoneally with either 10 mg/kg MDPV or 10 mg/kg methylone, and brains and plasma were collected at the following time points: 1, 10, 15, 30, 60, and 120 minutes. Samples were then flash-frozen and stored at -70°C until analysis. Samples were spiked with deuterium-labeled MDPV or methylone (internal standards), and the drugs were extracted from tissue using a previously published solid phase extraction method. Chromatographic separation of the compounds was achieved using a HILIC column with a gradient elution of acetonitrile and 5 mM ammonium formate at a flow rate of 0.2 mL/min. Mass spectrometric detection utilized a Shimadzu IT-TOF system with the electrospray source running in positive mode. Data acquisition utilized a direct MS-MS method using a precursor ion of 276.3 m/z for MDPV and methylone. The calibration curve ranged from 100 ng/ml to 0.1 ng/ml. These conditions allowed for a lower limit of detection (LLOD) of less than or equal to 1 ng/mL and a lower limit of quantification (LLOQ) of less than or equal to 5 ng/mL for MDPV and methylone. MDPV and methylone peak concentrations in plasma were seen immediately at 1 min, while brain concentrations peaked at 15 min; however, MDPV reached higher concentrations in the brain the methylone. This is consistent with MDPV’s higher lipophilicity (logP value). In conclusion, the pharmacokinetic profile of these drugs reflects a quick uptake and distribution of the drugs to the brain, followed by the quick distribution out of the brain, which likely contributes to the binge use of these drugs.

Introduction: Coenzyme Q10 (CoQ10) is a fat-soluble substance (ubiquinone) which has a bright orange color in appearance and is widely distributed (ubiquitous) in animals and many bacteria. CoQ10’s presence is most prevalent in mitochondria and it is involved in aerobic cellular respiration and aides in converting ingested nutrients into a readily accessible form of energy, specifically ATP (adenosine triphosphate). CoQ10 is supplied through our diets and can be found more in dark leafy green vegetables, fish and organ meats. CoQ10 supplementation should be beneficial due to its characteristic antioxidant scavenging of free radicals that our body produces while in the cellular respiration process for generating energy from nutrients. Although CoQ10 has great antioxidant benefit, a challenge remains for supplement manufacturers to deliver a sufficient does of this sparingly soluble molecule. Dietary supplements do not have the significant FDA oversight that exists for legend drugs, resulting in significant variability within and between brands. The main hypothesis of this project is that commercially available CoQ10 supplements don’t deliver a sufficient mass of CoQ10 when compared to the labelled quantity. Methods: To test this hypothesis, the group purchased and tested 14 commercially available CoQ10 supplements with each serving containing 100 mg of active, choosing a variety of drug delivery systems (DDS) and also included one in-house product, which contained 70 mg of active. The DDSs examined consisted of 7 soft shell gelatin (SSG) capsules (the most common type available), 3 hard shell gelatin (HSG) capsules, 3 tablets (tab), 1 powder, and 1 suspension. Each DDS was placed into a 500 mL volumetric flask (VF) into an aqueous of 0.1 N HCl acid and 0.1% Tween 80, using a standard FDA dissolution method. To facilitate drug release, the contents were removed from the HSG capsules; the SSG capsules were perforated; and the tabs were broken/crushed. After this, a magnetic stir bar was placed into each flask and all DDS samples were vigorously stirred for 30-45 minutes, including being inverted every 10 minutes to further facilitate dissolution of CoQ10 from each DDS. Filtered samples were obtained and the samples were analyzed by a reverse-phase High Performance Liquid Chromatography that was previously developed by this research group. Results and Conclusions: Only two of the 15 products evaluated had significant availability (mean > 50%) of CoQ10; one soft gelatin capsule (Product A, dissolved a mean of 68.57%), and the suspension (Product K, dissolved a mean of 56.71%). All of the other products averaged less than 4% dissolution of the labelled amount (range of values 0.19% to 3.64%). The in-house formulated HSG capsule (Product Q) released a mean amount equal to 8.11% of label (more than twice the percentage of the poorly performing commercial products). The consistency of the products was also variable, with product A having a range of 1.7 to 192 mg of CoQ10 released; Product K had a range of 35.8 to 76.1 mg of drug released. The group concluded that there are acceptable products available, but that most have significant performance issues.

Stroke is the third leading cause of death and disability in the United States. At present, intravenous administration of tissue plasminogen activator (t-PA) is the only thrombolytic therapy approved by the FDA for the treatment of acute ischemic stroke. There are no other effective treatments available so far. The discovery of new drugs and new treatments for stroke to reduce mortality and disability is an urgent medical research priority. In this study, the protective effects and mechanisms of two novel agents Gly14 humanin (HNG) and necrostatin-1 (Nec-1) were examined. HNG, a highly potent neuropeptide against amyloid toxicity, exhibited anti-apoptotic properties on cerebral ischemia injury. HNG reduced infarct volume after ischemia/reperfusion injury with pre-treatment or post-treatment (i.c.v. and i.p.) in a middle cerebral artery occlusion model in mice and decreased neurological deficits induced by ischemia. The protection of HNG was mediated by inhibiting ERK activation and activating PI3K/Akt pathway. Inhibition of the PI3K/Akt pathway blocked the protective effects of HNG. Nec-1 is a specific inhibitor of necroptosis, a newly identified cell death, and was reported to reduce infarct volume even when it was administered at 6 h post-ischemia in a mouse stroke model. Interestingly, this small molecule protected against glutamate-induced oxidative toxicity in a hippocampal HT-22 cell line. It inhibited the translocation of apoptosis-inducing factor from the mitochondria to the nucleus, increased the cellular glutathione level, and decreased free radical formation after glutamate treatment. More importantly, Nec-1 inhibited BNIP3-mediated caspase-independent cell death. Cerebral ischemia/reperfusion injury involves the activation of different pathways that lead to neuronal cell death. Given this multifactorial pathnogenesis, it is possible that a cocktail of neuroprotective agents would be superior to monotherapy. In this study, a cocktail of HNG and Nec-1 was examined in vitro and in vivo. HNG and Nec-1 exerted synergistic neuroprotection on oxygen-glucose deprivation-induced cell death and cerebral ischemia/reperfusion injury. This study provided a new therapeutic strategy for the treatment of stroke by the combination of anti-apoptosis and anti-necroptosis therapy.

The bacterial ribosome is a target for inhibition by numerous antibiotics. Neomycin and paromomycin are aminoglycoside antibiotics that specifically stimulate the misreading of mRNA by binding to the decoding site of 16S rRNA in the 30S ribosomal subunit. Recent work has shown that both antibiotics also inhibit 30S subunit assembly in Escherichia coli and Staphylococcus aureus cells. This work describes the characteristics of an assembly intermediate produced in E.coli cells grown with neomycin or paromomycin. Antibiotic treatment stimulated the accumulation of a 30S assembly precursor with a sedimentation coefficient of 21S. The particle was able to bind radio labeled antibiotics both in vivo and in vitro. Hybridization experiments showed that the 21S precursor particle contained 16S and 17S rRNA. Ten 30S ribosomal proteins were found in the precursor after inhibition by each drug in vivo. In addition, cell free reconstitution assays generated a 21S particle during incubation with either aminoglycoside. Precursor formation was inhibited with increasing drug concentration. This work examines features of a novel antibiotic target for aminoglycoside and will provide information that is needed for the design of more effective antimicrobial agents.

There has been a desire to accurately interpret the inhaled pharmacokinetic (PK) profiles of drugs in humans to aid successful inhaled drug and product developments. However, challenges are layered, as 1) the drug dose delivered to the lung (DTL) from inhalers is a portion of the formulated dose but rarely determined; 2) lung delivery and regional deposition differ, depending on drug, formulation and inhaler; 3) drugs are not only absorbed from the lung but may also be from the gastrointestinal (GI) tract; and 4) in addition to absorption into the systemic circulation, multiple non-absorptive processes also eliminate drugs from the lung, such as mucociliary clearance, metabolism, phagocytosis and tissue binding. Hence, this thesis project aims to develop new lung disposition model-based analyses to derive the meaningful kinetic descriptors for lung disposition from inhaled PK profiles in humans. Two approaches, curve fitting- and moment-based approaches, were developed. Both approaches modeled the kinetics of lung disposition rate-controlled by absorption (ka) and non-absorptive loss (knal), assuming no contribution of GI absorption. An exhaustive literature review found necessary data sets for three drugs, tobramycin, calcitonin and ciprofloxacin. In the curve fitting-based approach, each inhaled PK profile was fitted to the lung disposition model, while the DTL was obtained from corresponding -scintigraphic lung deposition and the kinetic parameters of systemic disposition were fixed by separate intravenous PK profile model analysis. In the moment analysis-based approach, the mean lung residence times (MLRT) and the DTL-based bioavailability (FL) were estimated and used to determine the ka and knal values in the lung disposition model, given FL = MLRTka = ka/(ka+knal). The ka and knal values were successfully derived for all the three drugs delivered by dry powder inhalers (DPIs) and/or nebulizers (NEB) through both approaches. Their “goodness-of-fit” was reasonably satisfactory. The ka values appeared to be primarily described by partition-based diffusion affected by the three hydrophilic drug’s molecular weight. In contrast, the knal values differed, yet appeared to become plausible, with a notion of additional non-absorptive confoundedness due to lung tissue binding (tobramycin) and metabolism (calcitonin), in addition to mucociliary clearance. The ka and knal values derived by the two approaches were comparable in majority of the cases. The success of these PK modeling analyses enabled further attempts to identify most influential attributes by simulation. The systemic PK and lung exposure profiles were predicted by simulation upon ±20 % changes in each of the DTL, ka and knal values to examine changes in the systemic PK metrics (Cmax, AUC and Tmax) and local lung exposure metrics (AUClung and LRT0.5). For all three drugs, the Cmax and AUC changes were identical to changes in the DTL without changing the Tmax. In contrast, impacts of the ka and knal changes differed between drugs, depending on the relative contribution of the rate constant to their sum (ka+knal). It appeared that the major contributor of the sum (ka+knal) was that rate-controlling the kinetics of lung disposition. In conclusion, this thesis project has successfully proposed two new approaches of curve fitting and moment-based analysis by accurately deriving the kinetic descriptors of lung disposition (ka and knal) for three drugs from the inhaled PK profiles in humans. Their applications were extended to predict likely changes in the systemic PK and local lung exposure metrics by simulation. While attempts should continue with more drugs, these approaches are believed to be useful in identifying critical attributes to determine the lung disposition kinetics and thus predicting the lung kinetic behavior and systemic PK profiles of new drug entities in humans.

RNA nanotechnology is an emerging field that holds great promise for advancing drug delivery and materials science. Recently, RNA nanoparticles have seen increased use as an in vivo delivery system. RNA was once thought to have little potential for in vivo use due to biological and thermodynamic stability issues. However, these issues have been solved by: (1) Finding of a thermodynamically stable three-way junction (3WJ) motif; (2) Chemical modifications to RNA confer enzymatic stability in vivo; and (3) the finding that RNA nanoparticles exhibit low immunogenicity in vivo. In vivo biodistribution and pharmacokinetics are affected by the physicochemical properties, such as size, shape, stability, and surface chemistry/properties, of the nanoparticles being delivered. RNA has an inherent advantage for nanoparticle construction as each of these properties can be finely tuned. The focus of this study is as follows: (1) Construction of diverse size and shape RNA nanoparticles with tunable physicochemical properties; (2) Investigation of the effect that size, shape, and nanoparticle properties have on in vivo biodistribution; (3) Development of drug encapsulation and release mechanism utilizing RNA nanotechnology; and (4) Establishment of large-scale synthesis and purification methods of RNA nanoparticles. In (1), RNA triangle, square, and pentagon shaped nanoparticles were constructed using the phi29 pRNA-3WJ as a core motif. Square nanoparticles were constructed with sizes of 5, 10, and 20 nanometers. The RNA polygons were characterized by AFM to demonstrate formation of their predicted geometry per molecular models. Furthermore, the properties of RNA polygons were tuned both thermodynamically and chemically by substitution of nucleic acid type used during nanoparticle assembly. In (2), the biodistribution of RNA nanosquares of diverse sizes and RNA polygons of diverse shapes were investigated using tumor models in nude mice. It was found that increasing the size of the nanosquares led to prolonged circulation time in vivo and higher apparent accumulation in the tumor. However, it was observed that changing of shape had little effect on biodistribution. Furthermore, the effect of the hydrophobicity on RNA nanoparticles biodistribution was examined in mouse models. It was found that incorporation of hydrophobic ligands into RNA nanoparticles causes non-specific accumulation in healthy organs, while incorporation of hydrophilic ligands does not. Lower accumulation in vital organs of hydrophobic chemicals was observed after conjugation to RNA nanoparticles, suggesting RNA has the property to solubilize hydrophobic chemicals and reduce accumulation and toxicity in vital organs. In (3), a 3D RNA nanoprism was constructed to encapsulate a small molecule fluorophore acting as a model drug. The fluorophore was held inside the nanoprism by binding to an RNA aptamer. The ability of the stable frame of the nanoprism to protect the fragile aptamer inside was evidenced by a doubling of the fluorescent half-life in a degrading environment. In (4), a method for large-scale in vitro synthesis and purification of RNA nanoparticles was devised using rolling circle transcription (RCT). A novel method for preparing circular double stranded DNA was developed, overcoming current challenges in the RCT procedure. RCT produced more than 5 times more RNA nanoparticles than traditional run-off transcription, as monitored by gel electrophoresis and fluorescence monitoring. Finally, large-scale purification methods using rate-zonal and equilibrium density gradient ultracentrifugation, as well as gel electrophoresis column, were developed.

The purpose of the project was to investigate the impact of IV and PO routes difference for MDZ, a prototypical CYP3A substrate, and two CYP3A inhibitors (CYP3AI) -FLZ and ERY-, on the magnitude and time course of their inhibitory metabolic DDI. Individual semi-PBPK models for MDZ, FLZ and ERY were developed and validated separately, using pharmacokinetic (PK) parameters from clinical/in-vitro studies and published physiological parameters. Subsequently, DDI sub-models between MDZ and CYP3AIs incorporated non-competitive and mechanism-based inhibition (MBI) for FLZ and ERY, respectively, on hepatic and gut wall (GW) CYP3A metabolism of MDZ, using available in-vitro/in-vivo information. Model-simulated MDZ PK profiles were compared with observed data from available clinical PK and DDI studies, by visual predictive check and exposure metrics comparison. DDI magnitude and time course for CYP3AI (IV vs. PO) followed by MDZ (IV vs. PO) at various time points were predicted by the validated semi-PBPK-DDI models. Two hypothetical CYP3A substrates and four CYP3AI (derived from MDZ, FLZ and ERY, with GW metabolism removed, hepatic metabolism reduced, or oral bioavailability (Foral) and/or elimination half-life (t1/2) modified) were also simulated to generalize conclusions. The final semi-PBPK-DDI models predict well the PK profiles for IV/PO MDZ in absence/presence of IV/PO CYP3AI, with deviations between model-predicted and observed exposure metrics within 30%. Prospective simulations demonstrate that: 1) CYP3A substrates, e.g., MDZ, are consistently more sensitive to metabolic inhibition after PO than after IV administration, due to pre-systemic hepatic and/or GW metabolism. For substrates without GW metabolism and limited hepatic metabolism, only a marginal route difference for substrate administration is observed. 2) For high-Foral CYP3AIs, e.g., FLZ, no inhibitor IV-PO route DDI differences are expected, unless they are given simultaneously with PO MDZ. 3) For low-Foral CYP3AIs, e.g., ERY, greater inhibition is expected after IV than after PO administration for IV MDZ, but is difficult to predict for PO MDZ. 4) In addition to Foral and plasma t1/2 of CYP3AIs, the DDI onset, peak and duration are determined by their oral absorption rate and by the resulting hepatic and/or GW concentration profiles relative to Ki for noncompetitive CYP3AIs, but by CYP3A kinetics (synthesis, degradation rate) for MBI CYP3AIs.

Growing resistance of bacteria towards antibiotics resulted in extensive research effort for development and application of new materials and techniques. Due to their unique properties, graphene quantum dots (GQDs) have attracted much attention and are a promising material with potential applications in many fields. One use of GQDs is as a photodynamic therapy agent that generates singlet oxygen. In this work, GQDs synthesized by focusing nanosecond laser pulses into a mixture of benzene and nickel(II) oxide were combined with methylene blue (MB) to eradicate Gram-negative Escherichia coli and Gram-positive Micrococcus luteus. Theoretical calculation of pressure evolution was calculated using the standard finite difference method. Detailed characterizations were performed with transmission electron microscopy (TEM), scanning electron microscopy (SEM), Fourier-transform infrared (FTIR), UV-Visible (UV-Vis), and photoluminescence (PL) spectra. Furthermore, singlet oxygen generation from MB-GQD mixture was investigated by measuring the rate of 9,10-anthracenediyl-bis(methylene) dimalonic acid photobleaching at 400 nm. Combining MB with GQDs caused enhanced singlet oxygen generation, leading to improved bacterial deactivation rate. The (3-(4,5-dimethylthiazol-2- yl)-2,5-diphenyltetrazolium bromide) (MTT) assay was used to determine if GQDs in dark conditions caused human cellular side-effects and affected cancer and noncancer cellular viability. We found that even high concentrations of GQDs do not alter viability under dark conditions. These results suggest that the MB-GQD combination is a promising photodynamic therapy agent that may be useful when antibiotics resistance is present.